This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Race Executes Key Contract for Israel Phase 2 AML Trial
- Contract signed to support Race’s Phase 2 relapsed/refractory Acute Myeloid Leukemia (AML) trial at the Chaim Sheba Medical Center in Israel
- Trialog Clinical Trials Ltd to supply trial drugs and provide other clinical services
- Clinical trial contract is in final stages with the first patient expected to be treated in Q3 CY 202
8 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has executed a contract with Trialog Clinical Trials Ltd, Israel, to support the coming combination Phase 2 Acute Myeloid Leukaemia trial. Trialog will supply the trial drugs (including Zantrene®) as well as provide other clinical services to Race and Chaim Sheba.
This 29 patient Phase 2 trial will use Zantrene® in a novel three drug combination which in preclinical studies showed superior efficacy in AML cells (ASX Announcement: 10 May 2021). The trial has received human ethics approval and will be supervised by Professor Arnon Nagler of the Chaim Sheba Medical Center. The first patient is expected to be treated in Q3 CY 2021.
The supply agreement has a maximum cost of USD$801,247 and will be invoiced in line with patient enrolment over the period 2021 – 2023.
Race Oncology looks forward to advising on the initiation of this trial in the near future, once it has executed the trial contract with the Chaim Sheba Medical Center.
This Phase 2 AML trial will run in parallel with a separate Australian Phase 2 trial in patients with extramedullary AML that is expected to begin treating patients in Q4 CY 2021 (ASX announcement: 2 June 2021).